about
Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT ProlongationMechanism of cardiotoxicity of halofantrinePharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humansAn Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval.Spectrum of antiarrhythmic response to encainide.Reducing inappropriate prescribing of sublingual nifedipine.Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.An accelerated pathway for targeted cancer therapies.QTc interval prolongation associated with intravenous methadone.Tolerance to the humoral and hemodynamic effects of caffeine in man.New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the Cardiac Arrhythmia Suppression Trial and its pilot study. The CAST and CAPS Investigators.Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.The FDA critical path initiative and its influence on new drug development.Time to replace Bazett's QT-correction.Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States.Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statisticsThe Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.Antiarrhythmic drugs.New concepts affecting the use of antiarrhythmic agents.One hundred years of drug regulation: where do we go from here?Regulatory and reimbursement innovation.Assessing cardiovascular drug safety for clinical decision-making.Clinical pharmacokinetics of moricizine.Overview of the clinical pharmacology of antiarrhythmic drugs.Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death.Evidence for the biotransformation of procainamide to a reactive metabolite.N-Desethyacecainide is a metabolite of procainamide in man; convenient method for the preparation of an N-dealkylated drug metabolite.Clinical pharmacology of old and new antiarrhythmic drugs.Role of plasma concentration monitoring in the evaluation of response to antiarrhythmic drugs.Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.Drug therapy. Tocainide.Disposition kinetics of encainide and metabolites.Drug therapy. Encainide.Clinical pharmacokinetics of encainide.Pharmacokinetics of moricizine HCl.Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure.Drug therapy. Flecainide.Clinical pharmacokinetics of disopyramide.
P50
Q27231482-94BF1E7C-EA1D-4C19-A71A-8C325D0B54EBQ28145054-B3272D80-CD81-4553-9D36-9CABA29774BFQ28238866-4B9A6D8C-D255-449A-946D-C39B04FFA38AQ31043880-1E792991-1CFF-49E5-8016-E967E1F3FF38Q33170065-109FABCE-488F-4B0A-939B-A1998CABA747Q33557092-B3F7AA1F-21FC-4ED4-9991-1AFACAD8AFD7Q34155242-C82B3D87-602F-4739-8A42-BFDFC9CFDC89Q34161861-45A3F87C-B623-4981-B7B8-77540E462557Q34267653-C3FC6F02-9BFC-41B7-AACA-BB728F7F20C3Q34275684-EEC5D28B-6D8F-404D-8029-7C0349D4E585Q34338535-B4E40E55-A889-4DFE-8039-7FA8D410402DQ34562449-B46BD439-160B-4E48-A753-7D51DF0CFC6EQ34734622-9142F21C-6E74-46D5-A781-6DD08C7134EBQ34999860-F642B85A-9211-4A8A-B118-88BB7C84456EQ35241065-B2693837-032E-400A-921C-06BD2FCBDA30Q37380061-23F1218B-777E-45DE-B7EF-1BCE7D1730B8Q37734863-5C5CB9C8-ED55-4AE8-979F-33CB44D4C1DDQ37774145-BB91AB04-86DA-4FAA-AC11-5EDBA8FEA092Q38023576-D09098DC-A1A9-412C-9160-8516574F2A8EQ38052586-F78E312C-43A7-403E-A351-750B3F10B768Q38088962-4CA33001-5441-4FF4-B302-D8669D964D84Q38099504-3C29566D-DF3C-4939-8AD1-ADCE191212C5Q38144488-3D2F0F6C-8387-4294-974D-C8306460732BQ38183295-64675A66-40B8-43FF-A353-151A5FFCDC63Q38596014-D53CE5BF-0EDE-46FE-AAD7-F3ECC3C84CB1Q38826956-52C7B70F-A874-4C39-A1E7-A9C398A69A06Q38919237-EEBAF944-8A8A-4C0F-B4E5-C4A575C1322DQ39278355-14610A89-9A6F-4E39-9B2F-E7EEE6FE19BCQ39281188-B3D632E2-6F36-4BB8-9B46-81E75D634700Q39434854-B8CFB0E2-772D-4B65-92AA-842E7FE7662CQ39531549-98026866-1735-444E-8DEF-24F62EE13100Q39587435-BEB385DE-0855-4EBD-A083-E548F0E11BA2Q39589187-541EAF13-3266-4778-961C-9DA0A8398655Q39590870-CCFF2A1A-AF33-45B2-A925-E9FE90173B8EQ39601873-AF2F4AF8-372B-44F4-B326-BB8AC5E1DF65Q39602740-3B65495E-B271-40B6-92EF-C86D323CF343Q39672056-A1C2414A-DA7F-4EF2-BE4F-38EA5DC9A660Q39676890-72FE1D10-1104-4014-BB7E-18729B54024DQ39734380-A264C0FC-6A46-488D-828C-9E2FCA1DE4EBQ39738825-3A694F58-F80C-4425-9E5D-D4AA7B5DFF8F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Raymond L Woosley
@ast
Raymond L Woosley
@en
Raymond L Woosley
@es
Raymond L Woosley
@nl
Raymond L Woosley
@sl
type
label
Raymond L Woosley
@ast
Raymond L Woosley
@en
Raymond L Woosley
@es
Raymond L Woosley
@nl
Raymond L Woosley
@sl
prefLabel
Raymond L Woosley
@ast
Raymond L Woosley
@en
Raymond L Woosley
@es
Raymond L Woosley
@nl
Raymond L Woosley
@sl
P1006
P214
P244
P1006
P106
P21
P213
0000 0000 2785 3880
P214
P244
P31
P3835
raymond-woosley
P496
0000-0002-2588-328X
P735
P7859
lccn-n85348299